Press Releases Year: - Any -201920182017201620152014 Items per page 102550 Date Title and Summary Additional Formats Toggle SummaryAug 06, 2019 Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results View HTML Toggle SummaryAug 02, 2019 Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryAug 01, 2019 Alder BioPharmaceuticals® to Present at Canaccord Genuity 39th Annual Growth Conference View HTML Toggle SummaryJul 30, 2019 Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2019 Financial and Operating Results View HTML Toggle SummaryJul 26, 2019 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryJul 11, 2019 Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention View HTML Toggle SummaryJul 08, 2019 Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society Meeting View HTML Toggle SummaryJun 19, 2019 Alder BioPharmaceuticals® to Webcast Upcoming Breakfast Symposium with Key Opinion Leaders View HTML Toggle SummaryJun 18, 2019 Alder BioPharmaceuticals® to Present at BMO Capital Markets 2019 Prescription for Success Healthcare Conference View HTML Toggle SummaryMay 24, 2019 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
